JP2020525426A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020525426A5 JP2020525426A5 JP2019570461A JP2019570461A JP2020525426A5 JP 2020525426 A5 JP2020525426 A5 JP 2020525426A5 JP 2019570461 A JP2019570461 A JP 2019570461A JP 2019570461 A JP2019570461 A JP 2019570461A JP 2020525426 A5 JP2020525426 A5 JP 2020525426A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- reducing agent
- reacting
- converting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C[C@](*)[C@@](CCC1C(C(C2)[C@@](C)(CCCC3)[C@]3C3*)C3=O)[C@@]1(C)[C@]2O Chemical compound C[C@](*)[C@@](CCC1C(C(C2)[C@@](C)(CCCC3)[C@]3C3*)C3=O)[C@@]1(C)[C@]2O 0.000 description 3
- HJIOHZIZYMNLRZ-LDCZGCDSSA-N CC[C@H]([C@H](C[C@@H](CC1)O)[C@@]1(C)C1C2C(CC[C@@H]3[C@H](C)CCC(O)=O)[C@H]3[C@H](C)C1)[C@H]2O Chemical compound CC[C@H]([C@H](C[C@@H](CC1)O)[C@@]1(C)C1C2C(CC[C@@H]3[C@H](C)CCC(O)=O)[C@H]3[C@H](C)C1)[C@H]2O HJIOHZIZYMNLRZ-LDCZGCDSSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523937P | 2017-06-23 | 2017-06-23 | |
| US62/523,937 | 2017-06-23 | ||
| PCT/US2018/039148 WO2018237350A1 (en) | 2017-06-23 | 2018-06-22 | METHODS AND INTERMEDIATES FOR PREPARING BILARY ACID DERIVATIVES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020525426A JP2020525426A (ja) | 2020-08-27 |
| JP2020525426A5 true JP2020525426A5 (enExample) | 2021-07-26 |
| JP7224307B2 JP7224307B2 (ja) | 2023-02-17 |
Family
ID=64691408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570461A Active JP7224307B2 (ja) | 2017-06-23 | 2018-06-22 | 胆汁酸誘導体の調製のための方法及び中間体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11066437B2 (enExample) |
| EP (1) | EP3642217A4 (enExample) |
| JP (1) | JP7224307B2 (enExample) |
| KR (2) | KR102831293B1 (enExample) |
| CN (1) | CN110945006A (enExample) |
| AU (1) | AU2018288883B2 (enExample) |
| BR (1) | BR112019027458A2 (enExample) |
| CA (1) | CA3067219A1 (enExample) |
| IL (2) | IL271343B2 (enExample) |
| WO (1) | WO2018237350A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013036835A1 (en) | 2011-09-08 | 2013-03-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| RS67266B1 (sr) | 2013-03-13 | 2025-10-31 | Sage Therapeutics Inc | Neuroaktivni steroidi i postupci za njihovu upotrebu |
| WO2015195967A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| SMT202100476T1 (it) | 2015-07-06 | 2021-09-14 | Sage Therapeutics Inc | Ossisteroli e metodi di uso degli stessi |
| JP6882996B2 (ja) | 2015-07-06 | 2021-06-02 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびそれらの使用の方法 |
| BR112018000129B1 (pt) | 2015-07-06 | 2024-01-09 | Sage Therapeutics, Inc | Compostos oxiesteróis, seus usos e composição farmacêutica |
| TN2018000106A1 (en) * | 2015-10-07 | 2019-10-04 | Intercept Pharmaceuticals Inc | Farnesoid x receptor modulators |
| SI3436022T1 (sl) | 2016-04-01 | 2022-08-31 | Sage Therapeutics, Inc. | Oksisteroli in postopki za uporabo le-teh |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| ES2884071T3 (es) | 2016-07-07 | 2021-12-10 | Sage Therapeutics Inc | 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA |
| MX392270B (es) | 2016-09-30 | 2025-03-24 | Sage Therapeutics Inc | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. |
| CN110267966B (zh) | 2016-10-18 | 2022-07-08 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| EP4105223B1 (en) | 2016-10-18 | 2025-04-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| WO2021155167A1 (en) * | 2020-01-31 | 2021-08-05 | The Johns Hopkins University | Bile acid-gcpii inhibitor conjugates to treat inflammatory diseases |
| PH12022552277A1 (en) | 2020-02-28 | 2024-03-04 | Kallyope Inc | Gpr40 agonists |
| US12215127B2 (en) | 2020-04-17 | 2025-02-04 | Cornell University | Compositions and methods for profiling of gut microbiota-associated bile salt hydrolase (BSH) activity |
| CA3178994A1 (en) | 2020-05-19 | 2021-11-25 | Iyassu Sebhat | Ampk activators |
| JP2023531726A (ja) | 2020-06-26 | 2023-07-25 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| CN112795615A (zh) * | 2021-02-03 | 2021-05-14 | 湖南醇康医药科技有限公司 | 一种诱变菌种以及微生物发酵制备熊去氧胆酸的方法 |
| WO2023288123A1 (en) * | 2021-07-16 | 2023-01-19 | Interecept Pharmaceuticals, Inc. | Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid |
| CN114045239B (zh) * | 2021-11-08 | 2023-09-29 | 浙江树人学院（浙江树人大学） | 具有二甲基乙酰胺降解能力的泛养副球菌ybh-7及应用 |
| AU2023257308A1 (en) * | 2022-04-21 | 2024-10-10 | Intercept Pharmaceuticals, Inc. | Uses of farnesoid x receptor agonists |
| WO2024163640A2 (en) * | 2023-02-01 | 2024-08-08 | Intercept Pharmaceuticals, Inc. | Methods and intermediates for the preparation of bile acid derivatives |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2403683A (en) * | 1942-04-25 | 1946-07-09 | Relchstein Tadeus | Compounds of the cyclopentanopolyhydrophenanthrene series and process of making same |
| US2554882A (en) | 1943-02-04 | 1951-05-29 | Reichstein Tadeus | 3-hydroxy-11-ketoetiocholanic acid and its esters |
| US3277121A (en) | 1964-05-04 | 1966-10-04 | Canada Packers Ltd | Conversion of delta11-steroids to 11-oxygenated steroids |
| DE3040634A1 (de) | 1980-10-29 | 1982-05-27 | Hoechst Ag, 6000 Frankfurt | Verfahren zur herstellung von 3 (alpha) -hydroxy-5- (beta) -pregnan-11,20-dion |
| DE10113257C1 (de) | 2001-03-19 | 2002-11-14 | Inst Mikrotechnik Mainz Gmbh | Elektrophoresevorrichtung und ihre Verwendung |
| US20080318870A1 (en) | 2007-06-19 | 2008-12-25 | Kythera Biopharmaceuticals, Inc. | Synthetic bile acid compositions and methods |
| HRP20180931T1 (hr) | 2013-05-14 | 2018-10-05 | Intercept Pharmaceuticals, Inc. | 11-hidroksil-6-supstituirani-derivati žučnih kiselina i njihovi aminokiselinski konjugati kao modulatori receptora za farnezoid x |
| CA2966885A1 (en) | 2014-11-06 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Bile acid analogs an fxr/tgr5 agonists and methods of use thereof |
| WO2016086115A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| HK1244708A1 (zh) | 2014-11-26 | 2018-08-17 | 英安塔制药有限公司 | 作爲fxr/tgr5激动剂的胆汁酸类似物及其使用方法 |
| RU2017130466A (ru) | 2015-02-11 | 2019-03-12 | Энанта Фармасьютикалс, Инк. | Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения |
| NZ735126A (en) | 2015-03-31 | 2022-10-28 | Enanta Pharm Inc | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| BR112018002499A2 (pt) | 2015-08-07 | 2018-09-18 | Intercept Pharmaceuticals Inc | método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica |
| TN2018000106A1 (en) | 2015-10-07 | 2019-10-04 | Intercept Pharmaceuticals Inc | Farnesoid x receptor modulators |
| CN107973834A (zh) | 2016-10-22 | 2018-05-01 | 合帕吉恩治疗公司 | 作为fxr/tgr5调节剂的胆酸衍生物 |
| US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
-
2018
- 2018-06-22 BR BR112019027458-8A patent/BR112019027458A2/pt unknown
- 2018-06-22 KR KR1020207002009A patent/KR102831293B1/ko active Active
- 2018-06-22 EP EP18821477.9A patent/EP3642217A4/en active Pending
- 2018-06-22 KR KR1020257022279A patent/KR20250109791A/ko active Pending
- 2018-06-22 IL IL271343A patent/IL271343B2/en unknown
- 2018-06-22 US US16/016,486 patent/US11066437B2/en active Active
- 2018-06-22 JP JP2019570461A patent/JP7224307B2/ja active Active
- 2018-06-22 CA CA3067219A patent/CA3067219A1/en active Pending
- 2018-06-22 WO PCT/US2018/039148 patent/WO2018237350A1/en not_active Ceased
- 2018-06-22 AU AU2018288883A patent/AU2018288883B2/en active Active
- 2018-06-22 CN CN201880047896.5A patent/CN110945006A/zh active Pending
-
2021
- 2021-06-08 US US17/342,057 patent/US20220127302A1/en active Pending
-
2023
- 2023-07-13 IL IL304455A patent/IL304455A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020525426A5 (enExample) | ||
| CN105518011B (zh) | 氨基磷酸酯类衍生物制备方法及其中间体和中间体的制备方法 | |
| JP2022133462A5 (enExample) | ||
| JP2010513494A5 (enExample) | ||
| JP5371033B2 (ja) | ３官能ニトリルオキシドおよびその製造方法 | |
| JP2013505259A5 (enExample) | ||
| WO2006046499A1 (ja) | インドリン化合物およびその製造方法 | |
| CZ20001613A3 (cs) | Způsob výroby oxazolidinonů | |
| WO2012006964A1 (zh) | 恩替卡韦的合成方法及其中间体化合物 | |
| KR102266680B1 (ko) | 벨리노스테트의 다형태 및 이의 제조 방법 | |
| JP2019214626A5 (enExample) | ||
| JP2008050321A (ja) | 光分解性カップリング剤 | |
| JP6289479B2 (ja) | ２−アミノ−４，６−ジメトキシベンズアミド及び他のベンズアミド化合物の合成方法 | |
| TWI343909B (en) | Process for making galantamine | |
| WO2002051781A1 (fr) | Procede permettant de preparer un compose d'halohydrine optiquement actif | |
| WO2018088527A1 (ja) | 新規トリチル保護剤 | |
| JP2009504800A5 (enExample) | ||
| JP6322350B1 (ja) | 新規トリチル保護剤 | |
| CN101220070B (zh) | 肌苷及其制造方法 | |
| JP2016535039A5 (enExample) | ||
| JP2020529457A5 (enExample) | ||
| JP5384353B2 (ja) | アリールオキシプロピルアミンおよびヘテロアリールオキシプロピルアミンを合成する方法 | |
| CN1360574A (zh) | 制备三环氨基醇衍生物的方法 | |
| JP2017514846A5 (enExample) | ||
| CN105198832A (zh) | 一种盐酸阿考替胺的制备方法 |